Table 1

Baseline demographics and disease characteristics for patients in BUILDER-1 part 1 (placebo-controlled phase, 12 weeks)

Placebo
n=51
TCZ 8 mg/kg
n=51
Age, years, mean (SD)42.7 (12.6)41.6 (11.2)
Male, n (%)40 (78)36 (71)
Geographical region, n (%)
 North America11 (22)12 (24)
 Rest of world40 (78)39 (76)
Positive HLA-B27 status, n (%)45 (88)43 (84)
AS duration, y, mean (SD)7.5 (8.1)5.4 (6.1)
Swollen joints ≥1, n (%)30 (59)33 (65)
BASDAI score, mean (SD)6.8 (1.3)6.6 (1.3)
CRP, mg/dl, mean (SD)1.7 (1.8)1.6 (2.2)
CRP, mg/dl, median1.10.8
  • BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein; TCZ, tocilizumab.